How we wish to be cited:
Focus on folate
The
classical picture of severe deficiency of cobalamin and/or folate is
inhibition of cell division in prophase (1); the result is few big
cells, macrocytes or megalocytes. The deficiency affects all tissues
with dividing cells, producing anemia, infertility and thin vulnerable
mucous membranes (1,2). In non-dividing cells, polyneuropaty due to
defective maintenance of myelin sheaths is widely recognized (3). In a
modern post-industrial society, deficiency states of cobalamin and
folate are mainly a concern of primary health care; even preclinical
deficiencies may produce infertility, miscarriages, and lesions of the
fetus. However, elderly people provide the main part of deficiency
patients (4). Since folate treatment may mask cobalamin deficiency, it
is suggested that folate monotherapy is abandoned; every patient treated
with folate should also be treated with cobalamin. Likewise, cobalamin
deficiency should always be treated with both cobalamin and folate. |
| Figure The giant nucleus (2x46 chromosomes) of a neutrophil leukocyte released from the bone marrow in the G2 stage of cell division is prone to hypersegmentation, a classical feature in cobalamin/folate deficiency. |
For about 50 years, it has been considered an error of the art to medicate with folate alone, without cover up with cobalamin (5). Conversely, it is becoming increasingly evident, that it is an error of the art to medicate with cobalamin without simultaneous folate therapy; out of 38 patients with apparent monodeficiency of cobalamin, the therapeutic effect of vitamin B12 alone was blocked by an incipient folate deficiency in five patients (6). Likewise, cobalamin monotherapy normalized methylmalonic acid in 87% of elderly patients with suspected deficiency but only 21% of associated homocysteine values; addition of oral folic acid normalized all homocysteine values (4,7).
If cobalamin/folate deficiency is allowed to progress, the deficiency states become crippling and life threatening, as suggested by the name of the index disease, pernicious anemia. In contrast, the cost of treatment of deficiency in early stages amounts to less than one cigarette per day (8). It is reasonable to assume that most residents will be able to bear this burden themselves, without subvention from the society. In contrast, it is up to society to secure, that the information from the health care system is adequate and balanced. Furthermore, the vitamin preparations on the market should be monitored for adequate bioavailability for both healthy persons and those with e.g. achylia due to atrophic gastritis.
Karin Björkegren
References
Published January 20, 2004